title: [Microsurgical resection of glioblastoma guided with intraoperative fluorescein: a Retrospective evaluation].
abstract: OBJECTIVE
  To evaluate the influence of the use of sodium fluorescein (FLS-Na) in surgery of glioblastoma (GB) on the degree of tumor resection and survival in patients treated at the National Institute of Neoplastic Diseases.
  
  
  METHODS
  A total of 238 cases of GB treated between 2008 and 2013 were reviewed and 150 cases of GB who underwent surgical resection with clinicopathological information and adequate follow-up were selected.
  
  
  RESULTS
  The mean age was 51 years, 58.7% of the cases presented a Karnofsky score of at least 90. FLS-Na was administered in 80 cases (53.3%) and a subtotal and total resection was obtained in 69 (46%) and 81 (54%) cases, respectively. The group that received FLS-Na obtained higher rates of total resection than the group operated with white light alone (77.5 vs 27.1%, p<0.001). The median overall survival (OS) was higher in the group subject to total compared to subtotal resection (17 vs 7 months, p<0.001). The median OS in those who received FLS-Na was higher than in those who did not (15.0 vs 8 months, p=0.003). Other factors affecting OS were age (p=0.002), the Karnofsky score (p=0.052) and radiation therapy (p=0.016) and chemotherapy (p=0.011).
  
  
  CONCLUSIONS
  The microsurgical technique with administration of FLS-Na was associated with an increase in the rate of total resection and survival.
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Pamela
authors.initials: P
authors.lastname: García-Corrochano
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Castañeda
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Enrique
authors.initials: E
authors.lastname: Orrego
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Pedro
authors.initials: P
authors.lastname: Deza
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Hugo
authors.initials: H
authors.lastname: Heinicke
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Sandro
authors.initials: S
authors.lastname: Casavilca
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Miluska
authors.initials: M
authors.lastname: Castillo
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Karen
authors.initials: K
authors.lastname: Cortez
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Carolina
authors.initials: C
authors.lastname: Belmar
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Ketty
authors.initials: K
authors.lastname: Dolores
authors.affiliation: Oncosalud, AUNA, Lima, Perú
authors.forename: Claudio
authors.initials: C
authors.lastname: Flores
authors.affiliation: Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
authors.forename: Luis
authors.initials: L
authors.lastname: Ojeda
mesh_terms: D001932:Brain Neoplasms / Q000601:surgery*; D005260:Female; D019793:Fluorescein / Q000627:therapeutic use; D005909:Glioblastoma / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D019793:Fluorescein